Added to YB: 2024-06-28
Pitch date: 2024-06-27
RLAY [bullish]
Relay Therapeutics, Inc.
+40.41%
current return
Author Info
Steve Wagner provides in-depth analysis of my favorite individual companies. Sign up for the newsletter.
Company Info
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
Market Cap
$1.6B
Pitch Price
$6.31
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.21
P/E
-5.24
EV/Sales
122.62
Sector
Biotechnology
Category
growth
This Biotech Stock Could Double By Year-End 2024 - Relay Therapeutics, Inc.
RLAY: AI-driven drug discovery co. RLY-2608 shows promise in breast cancer trials w/ 86% CBR at 600mg BID + fulvestrant. 4/24 patients w/ partial response. Versatile PI3Kα inhibitor potential for multiple cancers. Q4 2024 data readout crucial. $750M cash runway to 2H 2026. High-risk/high-reward biotech play w/ significant market potential if successful.
Read full article (6 min)